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Abstract
A 7’9 yoev!o nan eas trearev: nit’ Interferer wore orronic
mye/ogenous leuKemia anti oeveioped severe parkinson’sm that
resolved after Interferon alpha was stopped. Carbidopa-levodopa
was associated with early improvement, but discontinuation did not
result in worsenncy of the parkinsonism
Introduction
Two forms cf recombinant interferon ( IFN alpha. IFN alpha 2a and
IFN alpha 2b, are used in a variet of disorders. including hairy-cell
leukemia, hepatitis, AIDS-related Kaposi’s sarcoma, chronic mvel
ogenous leukemia, and melanorna. Reported adverse neurological
effects of IFN alpha ha\e included tremor. mental deterioration,
mood and behavioral changes, cortical blindness. leukoencephal
opath. Bell’s palsy. and coma* We report a patient who
developed severe parkinsomsm that resolved after treatment with
IFN alpha 2b was stopped.
Case History
A 79 year-old man was treated with IFN alpha 2h, 3 million units
subcutaneously daily for chronic mvelogenous leukemia with the
Philadelphia chromosome. His past medical history included pros
tate cancer, hypertension. hvpercholesteroleniia. peptic ulcer dis
ease, and gout. His other medications included orneprazole, hydro
chlorothiazide, lisinopril, allopurinol and tolterodine. Early side
effects of IFN included mild nausea, anorexia and weight loss.
These symptoms abated ith a transient reduction in dose. lEN wa
subsequently increased to 6 million units daily At eight weeks of
treatment (cumulative IFN dose of 324 million unitst the patient
developed a resting tremor, follo\ ed by mild confusion and diffi
culty with ambulation, At twelve weeks of treatment cumulative
lEN dose of 486 million units) the resting tremor had worsened, He
developed greater difficulty walking and fell fi’equentlv. He re
ciuired help s ith activities of dail\ li\ ing. His dosage as again
reduced hut no improvement in symptoms was noted.
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After twel e ss ceks of treatment I cumulative tEN dose of 391
million Ut. he was unable to stand independently and was confused.
and was hospitalized. He was alert hut inattentive, ss ith soft,
indistinct speech. His verbal responses were confused and tangen
tial. He required assistance to sit, stand. and walk. He demonstrated
a parkinsonian gait. bradvkinesia, cogwheel rigidity, and a pi’omi—
nent tremor of the arms present at rest and with action and sustained
posture. Strength was intact. Examination of the cranial nerves.
sensation, and reflexes was intact. Serum electrolytes were normal.
BUN and creatinine were 39 and 1 .5 respectively. Magnesium,
phosphorus and calcium were within normal limits. Non-contrast
CT scan of the brain revealed mild cerebral atrophy, and a small old
infarct in the leO basal ganglia. MRI scan of the brain revealed mild
cerebral atrophy. a small old right pontine infarct, and as mall infarct
in the left basal ganglia. Th roid function tests and ammonia level
were normal. HTLV— I by ELISA was negative.
Interferon was stopped. Carbidopa-levodopa 25/100 mg three
times daily was started. After several days the patient’s mentation.
tremor, and ambulation had improved. He continued to improve as
an outpatient. C’arbidopa-levodopa was stopped after t o seeks
without worsening of symptoms. One month after stopping lEN the
patient felt he had returned to his pretreatment baseline. On
examination he showed no confusion. Speech was normal. He had
mild cogwheel rigidity and a postural tremor, hut no resting tremor.
His gait was mildly slow and stiff, which his wife said was his
baseline.
Discussion
Our patient developed parkinsonism after eight eeks of IFN alpha
treatment. The motor and cognitive d sfunction progressed to the
point of severe disability, These problems resolved after lEN alpha
was discontinued. Early treatment with carhidopa-levodopa was
associated with clinical improvement. but there was no worsening
when it s as stopped. This effect of lEN alpha has not been
emphasized in the medical literature. Mizoi and colleagues puI—
lished a Japanese—language report of parkinsonismn in a 52-year—old
woman treated for six months with lEN alpha therapy tlr chronic
hepatitis C. This patient benefited from carbidopa-levodopa.
Meyers and colleagues reported four patients who developed par
kinsonism after lEN alpha treatment for various malienancies. All
patients benefited trom carhidopa—le odopa. TaIpei and cul—
leacues i’eported t o patients ho de eloped extrapvramidal svmp
toms ‘a ith lEN alpha.
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Shuto and colleagues found that repeated administration of lEN
alpha in mice was associated with a 10% decrease in brain dopamine
levels, and an 1 8% decrease in 3,4-dihydroxyphenvlacetic acid
levels.9 The concluded that repeated administration of IFN alpha
inhibits dopaminergic neuronal activity. In susceptible patients.
such as those with underking parkinsonism. a partial reduction in
dopaminereic activit\ by IF\ alpha therap\ rna\ be enough to
produce an overt Park insonian disorder, Our patient had mildly
impaired gait at baseline. it is possible that he has mild underlying
parkinsonism making him more susceptible to IFN alpha toxicity.
Nlerimsky and colleagues suggested that neurological effect’S of
interferon iriav occur in cancer patients earlier than patients v ith
other diseases, and that the incidence of interferon toxicity on the
central ner\ ous system may he related to the dose and the age of the
patients.
Clinicians should he aware of the possibility of drug-induced
parkinsonism in patients treated with lEN alpha. especially those
‘.s ho alread have parkinsonian s\ mptoms or sums.
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On National Doctor’s Day
March 30, 2002
Mahalo nui ba for the care and comfort you offer
to our patients, their t’amilies, and loved ones.
The difference you make is not just one day out of the year.
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